托法替布治疗类风湿关节炎患者血液学变化分析
该分析基于六项III期随机对照试验(n=4271)和两项长期扩展研究(n=4858),评估托法替布治疗类风湿关节炎后中性粒细胞、淋巴细胞和血红蛋白的变化。III期研究中所有托法替布组平均中性粒细胞和淋巴细胞计数下降、血红蛋白升高,长期扩展研究中血红蛋白和中性粒细胞稳定,淋巴细胞下降约48个月稳定。血红蛋白升高与ESR和CRP下降相关,但血红蛋白变化与疲劳或活力无关。
要点
- 托法替布治疗可出现中性粒细胞和淋巴细胞计数下降、血红蛋白升高,长期治疗中多数指标稳定。
- 临床有意义的血红蛋白下降(≥3 g/dl或≤7 g/dl)在所有治疗组中发生率<1.0%。
- 血红蛋白变化与ESR和CRP变化相关,但与FACIT-F或SF-36活力评分仅弱相关。
核心结论
- 托法替布治疗类风湿关节炎引起小幅血液学参数变化,长期扩展研究中趋于稳定。
- 血红蛋白变化虽与ESR和CRP变化相关,但与疲劳或活力无关。
研究设计与样本
- 分析六项III期随机对照试验(n=4271)和两项长期扩展研究(n=4858)中类风湿关节炎患者。
- III期试验中托法替布5或10 mg每日两次、安慰剂或阳性对照,疗程最长24个月。
- 长期扩展研究中托法替布疗程最长84个月。
主要发现
- III期研究中所有托法替布治疗组平均中性粒细胞和淋巴细胞计数下降、平均血红蛋白水平升高。
- 长期扩展研究中血红蛋白水平和中性粒细胞计数稳定,淋巴细胞计数下降约在第48个月稳定。
- 血红蛋白升高与ESR和CRP水平下降相关。
- 临床有意义的血红蛋白下降(较基线≥3 g/dl或血红蛋白≤7 g/dl)在所有治疗组中发生率<1.0%。
- FACIT-F和SF-36活力评分与血红蛋白水平仅弱相关。
关键数值与推荐
- 临床有意义的血红蛋白下降定义为较基线≥3 g/dl或血红蛋白≤7 g/dl,在所有治疗组中发生率<1.0%。
临床怎么用
- 托法替布治疗类风湿关节炎期间应监测中性粒细胞、淋巴细胞和血红蛋白变化。
- 血红蛋白变化与ESR和CRP变化相关,但评价疲劳或活力改善不应仅依赖血红蛋白变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The aim of this analysis was to characterize changes in haematological parameters following tofacitinib treatment, and to compare changes in haemoglobin with markers of disease activity, fatigue and vitality. METHODS: Changes in neutrophil counts, lymphocyte counts and haemoglobin levels were analysed in patients with RA from six phase 3 randomized controlled trials (n = 4271) of tofacitinib 5 or 10 mg bd, placebo or active comparators of up to 24 months' duration, and two long-term extension (LTE) studies (n = 4858) of tofacitinib of up to 84 months' duration. Disease activity markers included CRP and ESR. Fatigue and vitality were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Short Form Health Survey-36 vitality domain scores. RESULTS: In phase 3 studies, mean neutrophil and lymphocyte counts decreased and mean haemoglobin levels increased in all tofacitinib treatment groups. Haemoglobin levels and neutrophil counts stabilized in the LTE studies, while lymphocyte count decreases stabilized at approximately month 48. Increased haemoglobin was associated with decreased ESR and CRP levels. Clinically meaningful reductions in haemoglobin levels (⩾3 g/dl from baseline or haemoglobin ⩽7 g/dl) occurred in <1.0% of patients in all treatment groups. FACIT-F and Short Form Health Survey-36 vitality scores were weakly correlated with haemoglobin levels. CONCLUSION: Small changes in haematological parameters were seen with tofacitinib treatment, which stabilized over time in the LTE studies. Changes in haemoglobin levels, although associated with changes in ESR and CRP, were not associated with fatigue or vitality.
引用
- Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2016. PMID: 28028154. doi:10.1093/rheumatology/kew329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。